202 related articles for article (PubMed ID: 37008946)
21. Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas.
Wallace PW; Conrad C; Brückmann S; Pang Y; Caleiras E; Murakami M; Korpershoek E; Zhuang Z; Rapizzi E; Kroiss M; Gudziol V; Timmers HJ; Mannelli M; Pietzsch J; Beuschlein F; Pacak K; Robledo M; Klink B; Peitzsch M; Gill AJ; Tischler AS; de Krijger RR; Papathomas T; Aust D; Eisenhofer G; Richter S
J Pathol; 2020 Aug; 251(4):378-387. PubMed ID: 32462735
[TBL] [Abstract][Full Text] [Related]
22. Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127).
Gupta S; Zhang J; Milosevic D; Mills JR; Grebe SK; Smith SC; Erickson LA
Endocr Pathol; 2017 Sep; 28(3):253-268. PubMed ID: 28646318
[TBL] [Abstract][Full Text] [Related]
23. Screening of a Large Cohort of Asymptomatic SDHx Mutation Carriers in Routine Practice.
Saie C; Buffet A; Abeillon J; Drui D; Leboulleux S; Bertherat J; Zenaty D; Storey C; Borson-Chazot F; Burnichon N; Vincent M; Favier J; Baudin E; Giraud S; Gimenez-Roqueplo AP; Amar L; Lussey-Lepoutre C
J Clin Endocrinol Metab; 2021 Mar; 106(3):e1301-e1315. PubMed ID: 33247927
[TBL] [Abstract][Full Text] [Related]
24. Succinate-Dehydrogenase Deficient Paragangliomas/Pheochromocytomas: Genetics, Clinical Aspects and Mini- Review.
Rusyn L; Kohn B
Pediatr Endocrinol Rev; 2017 Mar; 14(3):312-325. PubMed ID: 28508602
[No Abstract] [Full Text] [Related]
25. The phenotype of
Niemeijer ND; Rijken JA; Eijkelenkamp K; van der Horst-Schrivers ANA; Kerstens MN; Tops CMJ; van Berkel A; Timmers HJLM; Kunst HPM; Leemans CR; Bisschop PH; Dreijerink KMA; van Dooren MF; Bayley JP; Pereira AM; Jansen JC; Hes FJ; Hensen EF; Corssmit EPM
Eur J Endocrinol; 2017 Aug; 177(2):115-125. PubMed ID: 28490599
[TBL] [Abstract][Full Text] [Related]
26. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.
Neumann HP; Pawlu C; Peczkowska M; Bausch B; McWhinney SR; Muresan M; Buchta M; Franke G; Klisch J; Bley TA; Hoegerle S; Boedeker CC; Opocher G; Schipper J; Januszewicz A; Eng C;
JAMA; 2004 Aug; 292(8):943-51. PubMed ID: 15328326
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance and peculiarities of succinate dehydrogenase B and hypoxia inducible factor 1α expression in parasympathetic versus sympathetic paragangliomas.
Bernardo-Castiñeira C; Sáenz-de-Santa-María I; Valdés N; Astudillo A; Balbín M; Pitiot AS; Jiménez-Fonseca P; Scola B; Tena I; Molina-Garrido MJ; Sevilla MA; Beristein E; Forga L; Villabona C; Oriola J; Halperin I; Suarez C; Chiara MD
Head Neck; 2019 Jan; 41(1):79-91. PubMed ID: 30549360
[TBL] [Abstract][Full Text] [Related]
28. Positive Immunostaining for Succinate Dehydrogenase B (SDHB) in Paraganglioma Associated with Germline Mutation of SDHB, L157X and P236S.
Sato H; Inomoto C
Tokai J Exp Clin Med; 2020 Sep; 45(3):148-151. PubMed ID: 32901905
[TBL] [Abstract][Full Text] [Related]
29. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
Fischer A; Kloos S; Maccio U; Friemel J; Remde H; Fassnacht M; Pamporaki C; Eisenhofer G; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Zitzmann K; Bechmann N; Žygienė G; Richter S; Hantel C; Vetter D; Lehmann K; Mohr H; Pellegata NS; Ullrich M; Pietzsch J; Ziegler CG; Bornstein SR; Kroiss M; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
J Clin Endocrinol Metab; 2023 Sep; 108(10):2676-2685. PubMed ID: 36946182
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes.
Gill AJ; Benn DE; Chou A; Clarkson A; Muljono A; Meyer-Rochow GY; Richardson AL; Sidhu SB; Robinson BG; Clifton-Bligh RJ
Hum Pathol; 2010 Jun; 41(6):805-14. PubMed ID: 20236688
[TBL] [Abstract][Full Text] [Related]
31. Clinical Predictors of Malignancy in Patients with Pheochromocytoma and Paraganglioma.
Dhir M; Li W; Hogg ME; Bartlett DL; Carty SE; McCoy KL; Challinor SM; Yip L
Ann Surg Oncol; 2017 Nov; 24(12):3624-3630. PubMed ID: 28884434
[TBL] [Abstract][Full Text] [Related]
32. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas.
Amar L; Baudin E; Burnichon N; Peyrard S; Silvera S; Bertherat J; Bertagna X; Schlumberger M; Jeunemaitre X; Gimenez-Roqueplo AP; Plouin PF
J Clin Endocrinol Metab; 2007 Oct; 92(10):3822-8. PubMed ID: 17652212
[TBL] [Abstract][Full Text] [Related]
33. Germline mutations and genotype-phenotype correlation in Asian Indian patients with pheochromocytoma and paraganglioma.
Pandit R; Khadilkar K; Sarathi V; Kasaliwal R; Goroshi M; Khare S; Nair S; Raghavan V; Dalvi A; Hira P; Fernandes G; Sathe P; Rojekar A; Malhotra G; Bakshi G; Prakash G; Bhansali A; Walia R; Kamalanathan S; Sahoo J; Desai A; Bhagwat N; Mappa P; Rajput R; Chandrashekhar SR; Shivane V; Menon P; Lila A; Bandgar T; Shah N
Eur J Endocrinol; 2016 Oct; 175(4):311-23. PubMed ID: 27539324
[TBL] [Abstract][Full Text] [Related]
34. Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations.
Pollard PJ; El-Bahrawy M; Poulsom R; Elia G; Killick P; Kelly G; Hunt T; Jeffery R; Seedhar P; Barwell J; Latif F; Gleeson MJ; Hodgson SV; Stamp GW; Tomlinson IP; Maher ER
J Clin Endocrinol Metab; 2006 Nov; 91(11):4593-8. PubMed ID: 16954163
[TBL] [Abstract][Full Text] [Related]
35. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas.
Timmers HJ; Kozupa A; Eisenhofer G; Raygada M; Adams KT; Solis D; Lenders JW; Pacak K
J Clin Endocrinol Metab; 2007 Mar; 92(3):779-86. PubMed ID: 17200167
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
[TBL] [Abstract][Full Text] [Related]
37. SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations.
Jochmanova I; Wolf KI; King KS; Nambuba J; Wesley R; Martucci V; Raygada M; Adams KT; Prodanov T; Fojo AT; Lazurova I; Pacak K
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1421-1435. PubMed ID: 28374168
[TBL] [Abstract][Full Text] [Related]
38. Back to Biochemistry: Evaluation for and Prognostic Significance of SDH Mutations in Paragangliomas and Pheochromocytomas.
Gupta S; Erickson LA
Surg Pathol Clin; 2023 Mar; 16(1):119-129. PubMed ID: 36739159
[TBL] [Abstract][Full Text] [Related]
39. Novel SDHB and TMEM127 Mutations in Patients with Pheochromocytoma/Paraganglioma Syndrome.
Patócs A; Lendvai NK; Butz H; Liko I; Sapi Z; Szucs N; Toth G; Grolmusz VK; Igaz P; Toth M; Rácz K
Pathol Oncol Res; 2016 Oct; 22(4):673-9. PubMed ID: 26960314
[TBL] [Abstract][Full Text] [Related]
40. Differences in Clinical Manifestations and Tumor Features Between Metastatic Pheochromocytoma/Paraganglioma Patients With and Without Germline SDHB Mutation.
Cui Y; Ma X; Wang F; Wang H; Zhou T; Chen S; Tong A; Li Y
Endocr Pract; 2021 Apr; 27(4):348-353. PubMed ID: 34024343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
